SBRA Maintained at Sector Perform by Scotiabank, May 2026

Scotiabank maintained its Sector Perform rating on Sabra Health Care REIT (SBRA) on May 21, 2026, while raising its price target to $22 from $21. The analyst firm’s decision reflects confidence in the healthcare real estate sector despite near-term headwinds. SBRA trades at $20.71, down slightly from its previous close. This rating action signals steady fundamentals in the REIT’s portfolio of skilled nursing and senior housing facilities.

Scotiabank’s SBRA Analyst Rating and Price Target

Scotiabank’s maintained rating underscores a balanced outlook for Sabra Health Care REIT. The analyst firm raised its price target to $22 from $21, suggesting modest upside from current levels. This $1 increase reflects improved operational metrics and sector dynamics in healthcare real estate.

The Sector Perform rating means Scotiabank expects SBRA to move in line with the broader real estate sector. With a market cap of $5.22 billion, SBRA remains a significant player in healthcare REITs. The stock trades above its 50-day average of $20.33 and 200-day average of $19.29, indicating relative strength.

SBRA Financial Metrics and Valuation

Sabra Health Care REIT shows mixed financial signals. The company trades at a P/E ratio of 33.5, elevated compared to sector peers, while the dividend yield stands at 5.78%, attractive for income investors. Free cash flow per share reaches $1.45, supporting the dividend payout.

Meyka AI rates SBRA with a grade of B+, suggesting solid fundamentals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The company’s debt-to-equity ratio of 0.97 indicates moderate leverage typical for REITs.

Analyst Consensus and Market Outlook

Wall Street consensus on SBRA leans cautious. Among 11 analysts tracked, four rate the stock as Buy, while seven maintain Hold ratings. No analysts recommend selling. This split reflects uncertainty about near-term catalysts despite long-term sector tailwinds.

SBRA’s portfolio includes 416 real estate properties across skilled nursing, senior housing, and behavioral health facilities. The company manages 41,445 beds and units across the United States and Canada. Earnings are expected August 3, 2026, which may provide clarity on operational trends.

Price Performance and Technical Setup

SBRA declined 1.66% in the past day but gained 19.85% over the past year. The stock trades within a tight range, with a 52-week high of $21.28 and low of $17.08. Volume averaged 2.28 million shares daily, providing adequate liquidity for traders.

Technical indicators show mixed signals. The RSI sits at 51.8, neutral territory. The Stochastic oscillator reads 69.7, suggesting potential overbought conditions. Bollinger Bands range from $20.07 to $21.26, indicating consolidation near recent highs.

Final Thoughts

Scotiabank’s maintained Sector Perform rating and raised price target reflect steady confidence in Sabra Health Care REIT’s operational foundation. The $1 price target increase to $22 suggests modest upside, though the stock remains fairly valued at current levels. With a B+ Meyka grade, solid dividend yield, and balanced analyst consensus, SBRA appeals to income-focused investors comfortable with healthcare real estate exposure. The August earnings report will be critical for determining whether the stock can break above resistance and justify further upside.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.